Cargando…
Identification of novel human leukocyte antigen‐A*11:01‐restricted cytotoxic T‐lymphocyte epitopes derived from osteosarcoma antigen papillomavirus binding factor
Osteosarcoma is the most common malignancy of bone that affects young people. Neoadjuvant chemotherapy and surgery have significantly improved the prognosis. However, the prognosis of non‐responders to chemotherapy is still poor. To develop peptide‐based immunotherapy for osteosarcoma, we previously...
Autores principales: | Li, Dongliang, Toji, Shingo, Watanabe, Kazue, Torigoe, Toshihiko, Tsukahara, Tomohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447853/ https://www.ncbi.nlm.nih.gov/pubmed/30767336 http://dx.doi.org/10.1111/cas.13973 |
Ejemplares similares
-
HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor
por: Tsukahara, Tomohide, et al.
Publicado: (2009) -
Development of a T‐cell receptor multimer with high avidity for detecting a naturally presented tumor‐associated antigen on osteosarcoma cells
por: Watanabe, Kazue, et al.
Publicado: (2018) -
A quest for therapeutic antigens in bone and soft tissue sarcoma
por: Kawaguchi, Satoshi, et al.
Publicado: (2005) -
Development of an artificial antibody specific for HLA/peptide complex derived from cancer stem-like cell/cancer-initiating cell antigen DNAJB8
por: Tadano, Hiroki, et al.
Publicado: (2020) -
Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99
por: Kim, Young-Hee, et al.
Publicado: (2016)